Icon

JADENU (nda206910)- (90MG,180MG,360MG)

DEFERASIROX NOVARTIS PHARMS CORP
90MG,180MG,360MG
Yes No
2034-Nov-21 Expired
2020-Jan-23 None
None No
JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.
13 0 11
Total Other Developers 22
Drugs with Suitability No
90MG ** ** - - -
180MG ** ** - - -
360MG ** ** - - 7
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** **** *** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** *** ***** ********* ********** **** ********** ****** **************** *********** ***** ***** *. **., ************, - *****, ******* (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ***** ***** ******* *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ***** ***** ******* *** *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ********* ** ********* *****, *** *********** ** *******-**, ******-***, *********-**, ********, **************-** *****, *****, ***** (***) ***
****** ******* ******* ****** ******* *********** **** **. **-**, ****** **, ******** ****, *********, ****** ******* ******, ***** (***) ***
****** ****** ****** ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ******* * ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******* ********* ******* ********* *** *********** *** ****** ***, *********, *** ****** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.